youtube cover2.png


April 8, 2022

Olaris, Inc. Announces Presentation at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Olaris, Inc.  is pleased to announce that the company’s presentation on the identification of metabolic reprograming associated with CDK4/6 sensitivity and resistance has been selected for a poster presentation at the upcoming 2022 American Association for Cancer Research (AACR) annual meeting, to be held April 8th - 13th.

The presentation, led by Olaris Metabolite Scientist Dr. Chandrashekhar Honrao, will describe the recent results of a collaboration between Olaris and the Dana Farber Cancer Institute. Using a human breast cancer cell line model and isotope tracers, researchers determined that glucose metabolism was altered following treatment with two CDK4/6 inhibitors, palbociclib and abemaciclib. They also found that cells resistant to the drugs had alterations in different metabolic pathways, representing the first-ever evidence of metabolite signatures specific to two different CDK4/6 inhibitors.

View the presentation at

March 28, 2022

Olaris Grows Leadership Team with Key Executive Hires

Olaris, Inc. announced today that it has expanded its leadership team with key senior hires who will advance partnerships for and commercialization of its novel diagnostics with the potential to transform how diseases are diagnosed and treated.

Olaris' new additions include:

Russell Herndon as Chief Business Officer. Herndon has more than 30 years' experience leading innovative healthcare technology companies and initiatives.

Laura T. Housman as Chief Commercial Officer. Before joining Olaris, Housman spent more than 30 years driving access to innovation in healthcare focusing on diagnostics, therapeutics, and devices across a range of disease areas.

March 21, 2022

Olaris Announces Appointment of Shawn Ayube as Vice President of Operations

Olaris, Inc. announced today the appointment of Shawn Ayube, a 20-year veteran in the biopharmaceutical industry, as Vice President of Operations.

In his new role, Ayube will be in charge of driving scalability across the organization and lead the effort to strategically enhance Olaris’ R&D capabilities as well as steering talent management and leadership development.

February 8, 2022

Olaris CEO Presents at Truist Securities Life Sciences AI Symposium - Biotech & Tools

Olaris Founder and CEO Dr. Elizabeth O'Day will present virtually at the Truist Securities AI Symposium – Biotech & Tools. The symposium will take place virtually on Tuesday, March 1, 2022.

The presentation by Dr. O'Day will discuss the unique combination of metabolomics and machine learning used by Olaris to develop diagnostics to empower patients that they have the right diagnosis and are on the right treatment path.

In addition to speakers, the symposium also features 3 panels, with focuses on applying AI to synthetic biology and therapeutics, utilizing deep learning and quantum physics for drug development, and integrated platforms for AI-based drug discovery. The keynote address will feature a discussion by Pfizer covering the use of AI and pharma in development of the COVID vaccine. A full agenda for the event can be found at: .

You can access the presentation on the day of the conference by going to:

January 18, 2022

Olaris Partners with Thermo Fisher on Metabolomics Diagnostic Assay for Immune Response in Transplant Recipients

Olaris and Thermo Fisher Scientific are partnering to evaluate the feasibility of a machine learning and metabolomics–based diagnostic panel to assess risk of developing complications from overimmunosuppression in kidney transplant recipients

December 6, 2021

Olaris Presenting at SABCS 2021: Identifying Metabolic Biomarkers of Response in Early-Stage Breast Cancer Patients

Olaris presented new data on the identification of metabolic signatures in matched plasma and serum samples associated with tumor proliferation in early-stage breast cancer (eBC) patients treated with Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) at the upcoming San Antonio Breast Cancer Symposium® to be held December 7-10, 2021. The presentation, conducted in collaboration with Dr. Cynthia Ma, Professor of Medicine, Division of Oncology at Washington University in St. Louis, highlights the use of Olaris’ BoR platform to identify metabolic signatures associated with tumor proliferation, an indicator of treatment resistance, in eBC patients treated with CDK4/6i.

September 30, 2021

Olaris Appoints Nephrology and Transplant Expert Dr. Dirk Kuypers to SAB

Dr. Kuypers is Professor of Medicine and Chair of the Laboratory of Nephrology at the University of Leuven, Belgium. He is also the Head of the Department of Nephrology and Director of the Renal Transplantation Program at the University Hospitals Leuven, Belgium. Dr. Kuypers’ clinical and translational research has spanned renal allograft surveillance using protocol biopsies and biomarkers of allograft status to pre-clinical and clinical immunosuppressive therapy development. He founded the Leuven Renal Allograft Biobank, which contributes prospectively collected biological samples and clinical data to translational studies in kidney transplantation. 

May 12, 2021

Olaris Welcomes Dr. Leonardo Rodrigues as VP of Artificial Intelligence and Machine Learning

In his role, Dr. Rodrigues will lead the acceleration of Olaris’ data strategy for the continued development of novel diagnostics with the potential to transform how diseases are diagnosed and treated. He will also provide critical insight enabling Olaris to streamline its technology for companion diagnostic development with biopharma partners in clinical trials.

April 9, 2021

Olaris Announces Presentation on Metabolic Biomarkers of Response in Advanced GIST at American Association for Cancer Research (AACR) 2021 Annual Meeting

Olaris is pleased to announce the company’s presentation on the identification of metabolic signatures in plasma samples associated with therapeutic response in metastatic gastrointestinal stromal tumors (GIST) has been selected for poster presentation at the upcoming 2021 American Association for Cancer Research (AACR) annual meeting, to be held virtually April 10th - 15th.

The presentation, led by Olaris Metabolite Scientist Dr. Chandrashekhar Honrao, highlights the use of Olaris’ BoR platform to identify metabolic signatures correlated with overall survival and to predict response or resistance to treatment in patients with advanced GIST.

March 22, 2021

Olaris Joins Microsoft for Startups

As the newest member of of the technology leader's global program aimed at helping startups scale, Olaris will be steamlining BoR development in immune response, neurodegeneration, and oncology. Olaris will also expand collaboration opportunities within biotechnology and healthcare through Microsoft's global partnership ecosystem.

February 16, 2021

World-leading Breast Cancer Oncologists Cynthia Ma MD, PhD and Massimo Cristofanilli, MD to Join Olaris Scientific and Medical Advisory Board

Olaris has appointed Dr. Cynthia Ma of Washington University in St. Louis and Dr. Massimo Cristofanilli from Northwestern Medicine to its Scientific Advisory Board and Medical Advisory Board. Dr. Ma and Dr. Cristofanilli will provide guidance on commercializing Olaris’ successful research identifying metabolic signatures for response to CDK4/6 inhibitors and building a pipeline of clinically differentiated, high-value diagnostic solutions.

June 8, 2020

Olaris CEO Elected to Personalized Medicine Coalition Board of Directors

Dr. Elizabeth O’Day will lead personalized medicine investment and adoption efforts globally during three-year term  

May 13, 2020

Olaris CEO to Speak at Xconomy’s Xcelerating Life Sciences Boston Event

Olaris CEO Dr. Elizabeth O’Day will speak at Xcelerating Life Sciences Boston, an Xconomy virtual conference & networking event focused on biopharma’s future in digital health. Dr. O'Day will sit on the panel, “Managing the Patient in the World of Personalized Medicine.”

March 2, 2020

Olaris Announces Findings from Exploratory Analysis of Biomarkers that Predict Patient Responsiveness to Trastuzumab Therapy

Olaris’ metabolite profiling platform and machine learning algorithms have the potential to accurately indicate whether HER2-positive metastatic breast cancer patients will respond to trastuzumab therapy.

February 11, 2020

Olaris Announces Grant from The Michael J. Fox Foundation for Parkinson’s Research

Initial project focus on uncovering metabolic signatures associated with neurodegenerative disease to provide deeper insight into mechanisms involved in Parkinson’s and its progression.